← Evidence map

ArticleScientific reports2026

Real-world chemotherapy use and survival outcomes in postmenopausal HR+/HER2-breast cancer with low genomic risk (RS ≤ 25): a multicenter cohort study from China.

Chengye Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-world chemotherapy use and survival outcomes in postmenopausal HR+/HER2-breast cancer with low genomic risk (RS ≤ 25): a multicenter cohort study from China. | OpenQuestion